SCHEMBL3578655

SCHEMBL3578655

COc1ccc(C(C)C(O)O)c([N+](=O)[O-])c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ AKR1C3 P42330 3/20 0.44
▸ AKR1C2 P52895 3/20 0.44
▸ AKR1B10 O60218 1/20 0.43
▸ AKR1B1 P15121 1/20 0.43
▸ AKR1C4 P17516 1/20 0.43
▸ AKR1C1 Q04828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20970479 0.88 ALDH1A1 (0.50) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL10178021 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL2065858 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL1665674 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL14154117 0.84 ALDH1A1 (0.53) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL22897654 0.81 ALDH1A1 (0.50) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL15483808 0.81 MAPT (0.45) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL16285728 0.81 AKR1C3 (0.50) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL14947932 0.81 MEN1 (0.48) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A
SCHEMBL14791578 0.81 SMN1; SMN2 (0.49) ALDH1A1MAPK1SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 — — US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 ALDH1A1 577/4885MAPK1 2681/4885SMN1; SMN2 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback